For instance, in August 2025, Viking Therapeutics, a US-based company specializing in metabolic and endocrine disorder treatments, announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an investigational oral dual GLP-1/GIP agonist for obesity
For constipation one of the most frequent complaintsgradually increasing fiber while ensuring adequate hydration typically provides relief
Compounded semaglutide is a GLP-1 receptor agonist that mimics the action of naturally occurring hormone glucagon-like peptide-1
In terms of efficacy, after 24 weeks of treatment, the changes in body weight for different doses in the Retatrutide group were: -2.1% for the placebo group, -7.2% for the 1 mg group, -12.9% for the 4 mg group, -17.3% for the 8 mg group, and -17.5% for the 12 mg group
Commensal bacteria make GPCR ligands that mimic human signalling molecules
Always consult with a healthcare provider to determine if GLP-1 injections are appropriate for your specific needs